Given that there are no major, obvious differences in tolerability, efficacy on glycemic parameters, weight loss, or overt advantages regarding administration, it is likely that the use of LIXI in place of other GLP-1 agonists will be based on cost (79)
This is the beginning and this is interesting, but now we need to replicate these findings." But few experts are ready to get behind widespread off-label use of GLP-1 drugs
Lipfendra, administered as a once-daily oral tablet, provides an additional treatment option for adults who require further LDL-C reduction despite existing therapies
Patients on Tesamorelin who continue weekend binge patterns lose the visceral fat reduction at the week-12 Inbody scan
Realistically, retatrutide will not be available through regulated Australian channels before 2027 at the earliest
The GLP-1 journey: from discovery science to therapeutic impact